NASDAQ:ALKS

Alkermes Competitors

$18.50

+0.07 (+0.38 %)

(As of 11/27/2020 12:00 AM ET)

Add

Compare

Today's Range

$18.33

Now: $18.50▼

$18.57

50-Day Range

$15.39

MA: $17.18▼

$18.43

52-Week Range

$11.98

Now: $18.50▼

$21.86

Volume286,244 shs

Average Volume1.56 million shs

Market Capitalization$2.94 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.18

Alkermes (NASDAQ:ALKS) Vs. AMGN, GILD, VRTX, REGN, BIIB, and SGEN

Should you be buying ALKS stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Alkermes, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Seagen (SGEN).

Alkermes vs. Amgen Stock

Amgen (NASDAQ:AMGN) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.

Insider and Institutional Ownership

71.7% of Amgen shares are held by institutional investors. Comparatively, 83.4% of Alkermes shares are held by institutional investors. 0.4% of Amgen shares are held by company insiders. Comparatively, 4.5% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Amgen and Alkermes' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$23.36 billion	5.60	$7.84 billion	$14.82	15.17
Alkermes	$1.17 billion	2.51	$-196,620,000.00	$0.07	264.29

Amgen has higher revenue and earnings than Alkermes. Amgen is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amgen and Alkermes' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amgen	29.42%	95.55%	15.52%
Alkermes	-6.28%	9.35%	5.50%

Analyst Ratings

This is a summary of recent recommendations and price targets for Amgen and Alkermes, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	1	12	15	0	2.50
Alkermes	1	7	2	0	2.10

Amgen currently has a consensus target price of $254.08, suggesting a potential upside of 13.02%. Alkermes has a consensus target price of $20.50, suggesting a potential upside of 10.81%. Given Amgen's stronger consensus rating and higher possible upside, equities research analysts clearly believe Amgen is more favorable than Alkermes.

Volatility and Risk

Amgen has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.

Summary

Amgen beats Alkermes on 11 of the 14 factors compared between the two stocks.

Alkermes vs. Gilead Sciences Stock

Alkermes (NASDAQ:ALKS) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Insider and Institutional Ownership

83.4% of Alkermes shares are owned by institutional investors. Comparatively, 77.9% of Gilead Sciences shares are owned by institutional investors. 4.5% of Alkermes shares are owned by company insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Alkermes and Gilead Sciences' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.17 billion	2.51	$-196,620,000.00	$0.07	264.29
Gilead Sciences	$22.45 billion	3.35	$5.39 billion	$6.14	9.78

Gilead Sciences has higher revenue and earnings than Alkermes. Gilead Sciences is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alkermes and Gilead Sciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alkermes	-6.28%	9.35%	5.50%
Gilead Sciences	5.48%	37.77%	12.76%

Analyst Ratings

This is a breakdown of current recommendations for Alkermes and Gilead Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1	7	2	0	2.10
Gilead Sciences	2	15	10	0	2.30

Alkermes currently has a consensus price target of $20.50, suggesting a potential upside of 10.81%. Gilead Sciences has a consensus price target of $76.1538, suggesting a potential upside of 26.86%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Gilead Sciences is more favorable than Alkermes.

Volatility and Risk

Alkermes has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Summary

Gilead Sciences beats Alkermes on 11 of the 14 factors compared between the two stocks.

Alkermes vs. Vertex Pharmaceuticals Stock

Alkermes (NASDAQ:ALKS) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Insider and Institutional Ownership

83.4% of Alkermes shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 4.5% of Alkermes shares are owned by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Alkermes and Vertex Pharmaceuticals' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.17 billion	2.51	$-196,620,000.00	$0.07	264.29
Vertex Pharmaceuticals	$4.16 billion	14.16	$1.18 billion	$4.29	52.85

Vertex Pharmaceuticals has higher revenue and earnings than Alkermes. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alkermes and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alkermes	-6.28%	9.35%	5.50%
Vertex Pharmaceuticals	38.51%	28.55%	20.68%

Analyst Ratings

This is a breakdown of current recommendations for Alkermes and Vertex Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1	7	2	0	2.10
Vertex Pharmaceuticals	0	8	22	1	2.77

Alkermes currently has a consensus price target of $20.50, suggesting a potential upside of 10.81%. Vertex Pharmaceuticals has a consensus price target of $290.5862, suggesting a potential upside of 28.18%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Alkermes.

Volatility and Risk

Alkermes has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats Alkermes on 13 of the 15 factors compared between the two stocks.

Alkermes vs. Regeneron Pharmaceuticals Stock

Alkermes (NASDAQ:ALKS) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Insider and Institutional Ownership

83.4% of Alkermes shares are owned by institutional investors. Comparatively, 85.9% of Regeneron Pharmaceuticals shares are owned by institutional investors. 4.5% of Alkermes shares are owned by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Alkermes and Regeneron Pharmaceuticals' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.17 billion	2.51	$-196,620,000.00	$0.07	264.29
Regeneron Pharmaceuticals	$7.86 billion	6.98	$2.12 billion	$21.47	23.94

Regeneron Pharmaceuticals has higher revenue and earnings than Alkermes. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alkermes and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alkermes	-6.28%	9.35%	5.50%
Regeneron Pharmaceuticals	37.30%	26.71%	19.39%

Analyst Ratings

This is a breakdown of current recommendations for Alkermes and Regeneron Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1	7	2	0	2.10
Regeneron Pharmaceuticals	0	10	13	1	2.63

Alkermes currently has a consensus price target of $20.50, suggesting a potential upside of 10.81%. Regeneron Pharmaceuticals has a consensus price target of $628.52, suggesting a potential upside of 22.27%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Alkermes.

Volatility and Risk

Alkermes has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Summary

Regeneron Pharmaceuticals beats Alkermes on 14 of the 15 factors compared between the two stocks.

Alkermes vs. Biogen Stock

Alkermes (NASDAQ:ALKS) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Volatility and Risk

Alkermes has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

Insider and Institutional Ownership

83.4% of Alkermes shares are owned by institutional investors. Comparatively, 78.9% of Biogen shares are owned by institutional investors. 4.5% of Alkermes shares are owned by company insiders. Comparatively, 0.5% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Alkermes and Biogen's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alkermes	-6.28%	9.35%	5.50%
Biogen	35.63%	51.00%	23.54%

Analyst Ratings

This is a breakdown of current recommendations for Alkermes and Biogen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1	7	2	0	2.10
Biogen	5	15	13	0	2.24

Alkermes currently has a consensus price target of $20.50, suggesting a potential upside of 10.81%. Biogen has a consensus price target of $305.9032, suggesting a potential upside of 25.48%. Given Biogen's stronger consensus rating and higher possible upside, analysts clearly believe Biogen is more favorable than Alkermes.

Earnings and Valuation

This table compares Alkermes and Biogen's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.17 billion	2.51	$-196,620,000.00	$0.07	264.29
Biogen	$14.38 billion	2.61	$5.89 billion	$33.57	7.26

Biogen has higher revenue and earnings than Alkermes. Biogen is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Summary

Biogen beats Alkermes on 11 of the 14 factors compared between the two stocks.

Alkermes vs. Seagen Stock

Seagen (NASDAQ:SGEN) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.

Risk and Volatility

Seagen has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500.

Insider and Institutional Ownership

92.0% of Seagen shares are owned by institutional investors. Comparatively, 83.4% of Alkermes shares are owned by institutional investors. 31.1% of Seagen shares are owned by insiders. Comparatively, 4.5% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Seagen and Alkermes' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seagen	-25.17%	-18.32%	-15.49%
Alkermes	-6.28%	9.35%	5.50%

Analyst Recommendations

This is a summary of current ratings for Seagen and Alkermes, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seagen	1	6	11	1	2.63
Alkermes	1	7	2	0	2.10

Seagen currently has a consensus target price of $176.75, suggesting a potential upside of 4.51%. Alkermes has a consensus target price of $20.50, suggesting a potential upside of 10.81%. Given Alkermes' higher probable upside, analysts plainly believe Alkermes is more favorable than Seagen.

Valuation & Earnings

This table compares Seagen and Alkermes' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seagen	$916.71 million	33.26	$-158,650,000.00	($1.33)	-127.16
Alkermes	$1.17 billion	2.51	$-196,620,000.00	$0.07	264.29

Seagen has higher earnings, but lower revenue than Alkermes. Seagen is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Summary

Alkermes beats Seagen on 8 of the 15 factors compared between the two stocks.